Status:
COMPLETED
Carbamazapine for Inherited Erythromelalgia Patients With NaV1.7 Mutations
Lead Sponsor:
VA Connecticut Healthcare System
Conditions:
Erythromelalgia
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
This research study is designed to investigate brain response using fMRI scan, and behavioral responses, to treatment with the drug carbamazepine (CBZ) in patients with the painful sodium channelopath...
Eligibility Criteria
Inclusion
- diagnosis/symptoms of EM
- specific NaV1.7 sodium channel mutations (including S241T)
Exclusion
- patients with no identified NaV1.7 mutation
Key Trial Info
Start Date :
April 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2016
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT02214615
Start Date
April 1 2014
End Date
July 1 2016
Last Update
June 6 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Yale University
New Haven, Connecticut, United States, 06520
2
VA Connecticut Healthcare System
West Haven, Connecticut, United States, 06516